41 results about "Melatonin agonist" patented technology

This invention provides methods of administering (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclo-propyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder.

A method of treating depression comprising administering a melatonin agonist.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.

A method of treating depression comprising administering a melatonin agonist.

The invention relates to a pharmacologically active combination, having utility in treating insomnia patients, which comprises: (a) at least one first active ingredient selected from melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists; and (b) at least one second active ingredient selected from nicotine and nicotine receptor agonists; to use of a medicament containing component (a) with or without component (b) for alleviation of at least one adverse effect which occurs in a patient in the course of nicotine replacement therapy, or otherwise, selected from impairment of the quality of sleep, impairment of cognition and impairment of memory, as well as to a kit having utility in treating insomnia patients, which comprises components (a) and (b) in unit dosage form.

The invention provides an application of catechin (1) shown as a structural formula (I) or pharmaceutical thereof and a pharmaceutical composition thereof in preparing a melatonin receptor agonist, anapplication thereof in preparing medicines for preventing or treating central nervous system disease related to melatonin receptor, and an application in preparing medicines for preventing or treating depression.

The invention provides application of magnolo-4-O-beta-D-glucopyranoside (1) shown as the structural formula (I) or medicinal salts and pharmaceutical compositions thereof to preparing melatonin receptor agonists as well as preparing drugs for treating or preventing central nervous system diseases correlated with melatonin receptors. The magnolo-4-O-beta-D-glucopyranoside (1) is prepared through achemical synthesis method.

The invention provides four isoechinulin dimers (-)-uncarilins A(1a), (+)-uncarilins A(1b), (-)-uncarilin B(2a) and (+)-uncarilins B(2b) as shown in a structural formula (I), a pharmaceutical composition formed by a therapeutically effective amount of compound 1a/1b or 2a/2b and a pharmaceutically acceptable carrier or excipient, a preparation method of the compound 1a/1b or 2a/2b and the pharmaceutical composition thereof, a melatonin receptor agonist and an application of the isoechinulin dimmers in treatment or improvement of central nervous system diseases related to a melatonin receptor.

The invention belongs to the technical field of drugs and provides magnolol derivatives (1-7) as shown in a structural formula (I) or a pharmaceutical composition and application of the magnolol derivatives or the pharmaceutical composition in preparing a melatonin receptor agonist as well as application thereof in preparing drugs for treating or preventing melatonin receptor related central nervous system diseases.

The invention provides a polybenzyl derivative (1-12) shown as a structural formula (I) or a drug composition of the polybenzyl derivative (1-12), a preparation method of the drug composition, and application of the drug composition to preparation of a melatonin receptor agonist and preparation of drugs for treating or preventing central nervous system diseases related to melatonin receptors.

The invention provides a series of indole derivatives or stereoisomers, tautomers, nitrogen oxides, metabolic products and pharmaceutically acceptable salts or prodrugs thereof. The indole derivatives can be taken as melatonin receptor stimulants. The invention also discloses a pharmaceutical composition containing the compounds, and a use of the compounds or the pharmaceutical composition of the compounds in treating the functional disorder of the central nervous system of mammal and in particular human.

The invention relates to a pharmacologically active combination and a method of enhancing cognitive performance in a patient suffering from Alzheimer's disease comprising administering to said patient a cognitive performance-enhancing amount of melatonin or a melatonin agonist in a combination therapy with a nicotine receptor agonist.

The invention provides a preparation method of a ramelteon orally disintegrating tablet. The orally disintegrating tablet, which takes ramelteon as an active ingredient, is a melatonin receptor agonist and is mainly used for treating insomnia of being hard to fall asleep, and the orally disintegrating tablet also has a concrete curative effect on chronic insomnia and short-term insomnia. The invention belongs to the novel technical field of medicines, and relates to the ramelteon orally disintegrating tablet and the preparation method thereof. The orally disintegrating tablet provided by the invention is good in taste and disintegrating effect and is good in stability; a sample is prepared by virtue of common equipment in accordance with a conventional process; and the preparation method is easy to operate, mature in process, low in production cost and is applicable to large-scale industrial production.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.